TXK — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL123348	1.00	3/20
SCHEMBL123351	0.81	3/20
SCHEMBL123062	0.81	3/20
SCHEMBL124479	0.79	3/20
SCHEMBL123779	0.78	3/20
SCHEMBL148535	0.76	3/20
SCHEMBL122287	0.75	3/20
SCHEMBL123582	0.75	3/20
SCHEMBL147980	0.75	3/20
SCHEMBL124380	0.72	3/20
SCHEMBL122291	0.71	3/20
SCHEMBL124379	0.70	3/20
SCHEMBL122276	0.70	3/20
SCHEMBL122294	0.70	3/20
SCHEMBL123818	0.69	3/20
SCHEMBL147342	0.68	3/20
SCHEMBL123462	0.58	3/20
SCHEMBL123056	1.00	2/20
SCHEMBL123345	0.80	2/20
SCHEMBL123555	0.78	2/20

Clinical trials — most relevant to TXK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes	PHASE4	COMPLETED
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis	PHASE4	NOT_YET_RECRUITING
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate	PHASE2/PHASE3	WITHDRAWN
CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.	PHASE1/PHASE2	UNKNOWN
Protein Tyrosine Kinases (PTK) in Multiple Myeloma	PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.	PHASE2	COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study	PHASE1	UNKNOWN
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors	PHASE1	UNKNOWN
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers	PHASE1	RECRUITING
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer	EARLY_PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases	nan	COMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
Cutaneous JAK in Vitiligo and Acne Vulgaris.	nan	UNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia	nan	UNKNOWN
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TXK binder may also engage these)

Protein	Name	Similarity
P42682	—	1.000	P42682 →
P35991	—	0.998	P35991 →
FRK	Tyrosine-protein kinase FRK	0.997	landscape →
ITK	Tyrosine-protein kinase ITK/TSK	0.997	landscape →
BTK	Tyrosine-protein kinase BTK	0.995	landscape →
Q0VBZ0	—	0.995	Q0VBZ0 →
P41241	—	0.994	P41241 →
BMX	Cytoplasmic tyrosine-protein kinase BMX	0.994	landscape →
P00528	—	0.993	P00528 →
Q8JH64	—	0.993	Q8JH64 →
TEC	Tyrosine-protein kinase Tec	0.993	landscape →
O13147	—	0.993	O13147 →
Q03526	—	0.992	Q03526 →
P41239	—	0.992	P41239 →
Q64725	—	0.992	Q64725 →
P97504	—	0.992	P97504 →
P24604	—	0.992	P24604 →
CSK	Tyrosine-protein kinase CSK	0.991	landscape →
P32577	—	0.991	P32577 →
Q60629	—	0.991	Q60629 →
Q54Y55	—	0.991	Q54Y55 →
P43404	—	0.990	P43404 →
Q00655	—	0.990	Q00655 →
P42690	—	0.990	P42690 →
P48025	—	0.989	P48025 →
Q9V9J3	—	0.989	Q9V9J3 →
P31693	—	0.989	P31693 →
Q54RB7	—	0.989	Q54RB7 →
Q64434	—	0.989	Q64434 →
Q922K9	—	0.988	Q922K9 →